Here are three things to know:
1. His appointment to the board marks the first time Mr. Wehner has become a board member of a company since accepting the CFO position at Facebook in 2014, the report states. He previously served on the board of StubHub.
2. Alector, which was founded in 2013, aims to cure Alzheimer’s by stimulating the immune cells in the brain to clear away the harmful proteins associated with such diseases. The company is currently working with AbbVie on two potential treatments and hope to bring its drug development program to the clinic this year.
3. The board also appointed Richard Scheller, PhD, chief science officer and head of therapeutics of 23andMe, and Louis Lavigne, the former CFO of Genentech. CNBC reports the decision to appoint two CFOs may signal an impending public offer for Alector, which is backed by Google’s parent company Alphabet, Eli Lilly and Merck, among others.
More articles on health IT:
Meditech adds prescription pricing tool to EHR
Apple adds 2nd clinical laboratory to health records project
CHIME releases list of ‘Most Wired’ hospitals: Here are the top 10
